Can-Fite BioPharma (CANF) has released an update.
Can-Fite BioPharma reports that its lead drug candidate, Namodenoson, designed to treat liver and pancreatic cancer, as well as MASH, has secured patent protection until at least 2044, with ongoing clinical studies in place. The company has multiple patents approved globally and is conducting pivotal Phase III and IIb trials for advanced liver cancer and MASH respectively. Namodenoson has shown a strong safety profile and potential efficacy in other cancer types, with further trials planned to expand its therapeutic reach.
For further insights into CANF stock, check out TipRanks’ Stock Analysis page.
